Apixaban, marketed as Eliquis, is an anticoagulant medication used to prevent blood clots. Generic versions of apixaban are not yet available on the market [1].
When does Eliquis patent protection end?
The primary patents for Eliquis are set to expire in the United States in 2026 [2][3]. However, there are other secondary patents and exclusivities that could extend market protection beyond this date, potentially until 2031 [4]. These patents cover various aspects of the drug, including its formulation and method of use [4].
Why are companies challenging Eliquis patents?
Pharmaceutical companies, particularly those seeking to market generic versions, frequently challenge existing patents for brand-name drugs. This is done to try and invalidate or circumvent patent claims, thereby paving the way for earlier market entry of generic alternatives. The goal is to gain market share and offer a lower-cost option to consumers [4].
What are the challenges to launching generic apixaban?
Launching a generic version of a complex drug like apixaban involves navigating multiple patent expirations and potential litigation. Even after primary patents expire, secondary patents and ongoing legal disputes can create uncertainty regarding the exact timeline for generic availability. Companies must also successfully complete the generic drug approval process with regulatory agencies [4].
How do generic apixaban prices compare to Eliquis?
Currently, without generic availability, pricing is solely determined by the brand-name manufacturer. Once generic apixaban enters the market, prices are expected to decrease significantly. This is a common trend in the pharmaceutical industry, where generic drugs typically offer a more affordable alternative to their brand-name counterparts [1].
What are the alternatives to apixaban?
For patients needing anticoagulant therapy, several alternative medications exist. These include other direct oral anticoagulants (DOACs) such as rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Lixiana/Savaysa), as well as older anticoagulant classes like warfarin [5]. The choice of anticoagulant depends on individual patient factors, medical history, and physician recommendation [5].
What is the mechanism of action for apixaban?
Apixaban works by directly inhibiting Factor Xa, a key enzyme in the blood clotting cascade. By blocking Factor Xa, apixaban reduces the formation of thrombin, which is essential for fibrin clot formation, thereby preventing the development of dangerous blood clots [6].
What is the clinical data supporting apixaban?
Clinical trials, such as the ARISTOTLE trial, demonstrated that apixaban was non-inferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation, while also resulting in significantly lower rates of major bleeding [7]. Other trials have shown its efficacy and safety in different patient populations and for the treatment and prevention of venous thromboembolism [7].
What are the risks and side effects of apixaban?
The most significant risk associated with apixaban, like all anticoagulants, is bleeding. Patients may experience minor bleeding, such as nosebleeds or bruising, but serious or life-threatening bleeding can also occur [8]. Other potential side effects include anemia and dizziness [8].
Sources:
1. https://drugpatentwatch.com/
2. https://drugpatentwatch.com/drug/apixaban
3. https://www.drugpatentwatch.com/news/apixaban-patent-expiry-dates-and-generic-competition
4. https://drugpatentwatch.com/blog/understanding-drug-patent-expiration-and-generic-entry
5. https://www.nhs.uk/conditions/blood-clots/treatment/
6. https://www.ema.europa.eu/en/documents/assessment-report/eliquis-epar-scientific-conclusion_en.pdf
7. https://www.nejm.org/doi/full/10.1056/NEJMoa1009329
8. https://www.mayoclinic.org/drugs-supplements/apixaban-oral-route/side-effects/drg-20072783